Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ITM Solucin GmbH
M.D. Anderson Cancer Center
Advanced Accelerator Applications
Exelixis
Sanofi
Corcept Therapeutics
Grupo Espanol de Tumores Neuroendocrinos
Novartis
Ipsen
Sanofi
Children's Oncology Group
Novartis
University of California, Los Angeles
Montefiore Medical Center
Radiomedix, Inc.
Ipsen
Ipsen
Ipsen
Advanced Accelerator Applications
Novartis
Novartis
Philipps University Marburg
Novartis
AstraZeneca
Amgen
Novartis
Novartis
Collaborative Group for Adrenocortical Carcinoma Treatment
Novartis
Novartis
Corcept Therapeutics
Corcept Therapeutics
INSYS Therapeutics Inc
Corcept Therapeutics
Novartis
Yale University